Home › Biocept Signs Deal to Sell $2.2M in Stock, Warrants

Biocept Signs Deal to Sell $2.2M in Stock, Warrants

Aug 10, 2017

NEW YORK (GenomeWeb) – Biocept today said that it has signed an agreement to sell $2.2 million in stock and warrants to Hong Kong-based investment group Ally Bridge LB Healthcare Master Fund Limited.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Roche Patent Invalidation Affirmed in TB Testing Lawsuit Against Cepheid

  2. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  3. Sanofi Genzyme, PerkinElmer Launch Free Dx Program for Patients With Lysosomal Storage Disorders

  4. NanoString Announces $100 Million Term Loan Facility With CR Group

  5. BD Obtains CE Mark for Molecular TB, MDR-TB Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.